There is some fascinating stuff is happening with psychedelics right now. Psychedelic therapy has gone from wacky voodoo to solid science.
While psychedelic drugs like MDMA and psilocybin (aka magic mushrooms) have a long way to go before they hit mainstream acceptance, there is a ton of interesting stuff happening behind the scenes.
The negative perceptions are fading, and an entirely new industry is forming before our eyes.
For some investors, it’s a world they know nothing about and are too skittish to enter. And that’s fine. For them, the doors will remain closed. But for others, this is a gold rush.
Today’s Deep Dive is a very special one. It’s the first time we’ve done a Deep Dive on a company we’ve personally invested in through our ALTS 1 Fund, a company we’ve come to know quite well over the past few months. That company is Nucleus
While psychedelic drugs like MDMA and psilocybin have a long way to go before they hit mainstream acceptance, there is a ton of interesting stuff happening behind the scenes.
We create indices for eclectic modern alts. We’ve got a vinyl index, a whiskey index, and more. This helps us find the best buying opportunities for our alternative investment fund
We wrap everything up with a rich qualitative analysis. You’ll understand the pros & cons of investing in all sorts of alternative asset classes.
Disclaimer: The authors of Alt Assets, Inc. are not finance or tax professionals. They are self-taught accredited investors, sharing information, research, and lessons learned. The published content is unique, based on certain assumptions and market conditions at the time of publishing and is intended to serve solely as research, not financial advice. Alts I LLC (the “Fund”) is an affiliate of Alt Assets, Inc. and the Fund has conducted a private placement offering under Rule 506(c) of Regulation D of the Securities Act of 1933, as amended. The Fund may invest in one, several or all of the alternative asset classes that Alt Assets, Inc. publishes content on its site. Any published articles on Alt Assets, Inc. that an alternative asset has a “buy”, “pass”, “overvalued” or “undervalued” designation does not factor into the asset classes that the Fund through its manager ultimately invests in, and thus, any of the Fund’s investments that have positive designations on the Alt Assets, Inc.’s site are purely coincidental as the Fund is actively managed and guided by its own investment parameters as summarized in the relevant private placement memorandum.
